SCHEMBL20522394

SCHEMBL20522394

N#CC1CCN(c2ccccc2-c2ccc(F)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 7/20 0.58
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 2/20 0.43
HTR1A P08908 4/20 0.42
HTR2A P28223 1/20 0.42
HTR5A P47898 1/20 0.42
HTR6 P50406 1/20 0.42
PTGS2 P35354 1/20 0.39
EGLN2 Q96KS0 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
HPGD P15428 1/20 0.36
FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28348704 0.82 KDM4E (0.65) HTR7KDM4EALDH1A1HTR1AHTR6
SCHEMBL27850036 0.79 KDM4E (0.72) KDM4EALDH1A1EGLN2HPGD
SCHEMBL20494695 0.77 KDM4E (0.53) KDM4EALDH1A1HPGD
SCHEMBL941809 0.74 HTR7 (1.00) HTR7HTR1AHTR2AHTR5AHTR6
SCHEMBL28348705 0.73 KDM4E (0.53) KDM4EALDH1A1EGLN2HPGDFEN1
Hydrochloric Acid SCHEMBL8729997 0.72 KDM4E (0.55) KDM4EALDH1A1HTR1AEGLN2
SCHEMBL3554921 0.72 KDM4E (0.55) KDM4EALDH1A1EGLN2HPGD
SCHEMBL30389269 0.71 KDM4E (0.51) KDM4EALDH1A1EGLN2PDE3BPDE3A
SCHEMBL2072485 0.71 KDM4E (1.00) KDM4EALDH1A1HTR2AEGLN2HPGD
SCHEMBL28863083 0.70 HTR7 (0.47) HTR7HTR1AHTR2AHTR5AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 HTR7 3178/4885KDM4E 1773/4885ALDH1A1 1183/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT HTR7 3888/4885KDM4E 1119/4885ALDH1A1 1681/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS HTR7 3798/4885KDM4E 1078/4885ALDH1A1 1490/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 HTR7 4011/4885KDM4E 1254/4885ALDH1A1 1415/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT HTR7 4053/4885KDM4E 1160/4885ALDH1A1 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.